Cargando…

Combined linkage and association analysis of classical Hodgkin lymphoma

The heritability of classical Hodgkin lymphoma (cHL) has yet to be fully deciphered. We report a family with five members diagnosed with nodular sclerosis cHL. Genetic analysis of the family provided evidence of linkage at chromosomes 2q35-37, 3p14-22 and 21q22, with logarithm of odds score >2. W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lawrie, Alastair, Han, Shuo, Sud, Amit, Hosking, Fay, Cezard, Timothee, Turner, David, Clark, Caroline, Murray, Graeme I., Culligan, Dominic J., Houlston, Richard S., Vickers, Mark A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945548/ https://www.ncbi.nlm.nih.gov/pubmed/29755658 http://dx.doi.org/10.18632/oncotarget.24872

Ejemplares similares

Second cancer risk following Hodgkin lymphoma
por: Sud, Amit, et al.
Publicado: (2017)

Genome-wide homozygosity signature and risk of Hodgkin lymphoma
por: Sud, Amit, et al.
Publicado: (2015)

Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History
por: Sud, Amit, et al.
Publicado: (2017)

Genetics of classical Hodgkin Lymphoma
por: Schiavoni, Gianluca, et al.
Publicado: (2018)

HLA Associations in Classical Hodgkin Lymphoma: EBV Status Matters
por: Huang, Xin, et al.
Publicado: (2012)

Survivors at risk: Hodgkin lymphoma survivors at high risk of second cancers
por: Sud, Amit
Publicado: (2017)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

The molecular mechanisms of classic Hodgkin's lymphoma.
por: Felberbaum, Rachael S.
Publicado: (2005)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

Controversies in the Treatment of Classical Hodgkin Lymphoma
por: Eichenauer, Dennis A., et al.
Publicado: (2018)

The Grey Zones of Classic Hodgkin Lymphoma
por: Bosch-Schips, Jan, et al.
Publicado: (2022)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
por: Dogan, Ahmet
Publicado: (2022)

Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility
por: Sud, Amit, et al.
Publicado: (2017)

Bob-1 is expressed in classic Hodgkin lymphoma
por: Abd El All, Howayda S
Publicado: (2007)

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma
por: Relecom, Allan, et al.
Publicado: (2020)

MicroRNA signature in classical Hodgkin lymphoma
por: Paczkowska, Julia, et al.
Publicado: (2021)

Bone marrow involvement by classic Hodgkin lymphoma
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Aberrant synaptophysin expression in classic Hodgkin lymphoma
por: Im, Soyoung, et al.
Publicado: (2022)

Current directions in the treatment of classical Hodgkin lymphoma
por: Keller, Frank G., et al.
Publicado: (2023)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
por: Katsin, Mikalai, et al.
Publicado: (2023)

Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility
por: Sud, Amit, et al.
Publicado: (2019)

Polygenic risk scores to stratify cancer screening should predict mortality not incidence
por: Vickers, Andrew J., et al.
Publicado: (2022)

Contribution of Epstein–Barr Virus Latent Proteins to the Pathogenesis of Classical Hodgkin Lymphoma
por: Vrzalikova, Katerina, et al.
Publicado: (2018)

Treatment outcomes in classic Hodgkin lymphoma: 5‐year update from the Brazilian Hodgkin Lymphoma Registry
por: Biasoli, Irene, et al.
Publicado: (2023)

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future
por: Richardson, S. E., et al.
Publicado: (2011)

Hemophagocytic Lymphohistiocytosis in a Patient with Classical Hodgkin Lymphoma
por: Hyun, G., et al.
Publicado: (2016)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
por: Meti, Nicholas, et al.
Publicado: (2018)

Mucocutaneous Paraneoplastic Syndrome Secondary to Classical Hodgkin’s Lymphoma
por: Jurkovic, Jenna, et al.
Publicado: (2019)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
por: De Re, Valli, et al.
Publicado: (2019)

Cell-Free DNA for the Management of Classical Hodgkin Lymphoma
por: Camus, Vincent, et al.
Publicado: (2021)

Classical Hodgkin Lymphoma Presenting as a Sigmoid Mass
por: Caulkins, Heather, et al.
Publicado: (2021)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

Optimization of the first line treatment in classical Hodgkin's lymphoma
por: Brice, Pauline
Publicado: (2018)

Checkpoint CD47 expression in classical Hodgkin lymphoma
por: Gholiha, Alex Reza, et al.
Publicado: (2022)

Novel Approaches in Molecular Characterization of Classical Hodgkin Lymphoma
por: van Bladel, Diede A. G., et al.
Publicado: (2022)

An updated portrait of monocyte-macrophages in classical Hodgkin lymphoma
por: Ferrarini, Isacco, et al.
Publicado: (2023)

Case report: Composite mantle cell lymphoma and classical Hodgkin lymphoma
por: Wang, Hongyu, et al.
Publicado: (2023)

Composite lymphoma associating diffuse large B‐cell lymphoma with classical Hodgkin lymphoma
por: Lauwers, Maïlis, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0ld1ko3gqlo7nsb30usf89c8dt